This review examined the potential role of testosterone replacement therapy (TRT) in hypogonadal men following radical prostatectomy for prostate cancer, challenging the historical contraindication due to concerns about cancer recurrence. Several studies reviewed showed that TRT did not significantly increase prostate-specific antigen (PSA) levels or lead to biochemical recurrence, with
